Jean-Philippe Bürckert, Ph.D.

Chief Technology Officer at Ability Biotherapeutics

Speaker

Jean-Philippe Bürckert, PhD is an immuno-informatics expert and biotechnology executive specializing in computational antibody discovery and engineering. He earned his PhD at the Luxembourg Institute of Health and went on to found the Bioinformatics Consulting chapter at BISC Global in Boston, supporting more than 20 pharma and biotech partners. He later served as Director of Computational Immunology at Distributed Bio through its acquisition by Charles River Laboratories, and subsequently as Director of Bioinformatics at Charles River’s San Francisco site.

Today, Jean-Philippe is the co-founder and executive director of Voredos SRL (Leuven, BE), co-founder and CTO of Ability Biotherapeutics (Montreal, CA), and co-founder and CTO of Nanolynx Biologics (Basel, CH), where he leads the development of AI-driven antibody and nanobody platforms powering discovery of next-generation therapeutics.

• PhD in immuno-informatics at Luxembourg Institute of Health.
• 2018, started Bioinformatics Consulting chapter of BISC Global in Boston building antibody discovery and engineering platforms for over 20 pharma and biotech clients.
• 2019, Director of Computational Immunology at Distributed Bio throughout the acquisition by CRL in 2021.
• 2021 Director of Bioinformatics at CRL SF site.
• Co-founder and Executive Director of Voredos SRL in 2019, a immuno-informatics focused consulting firm in Belgium.
• Co-founder and CTO of Ability Biotherapeutics in Montreal Canada in 2023.
• Co-Founder and CTO of Nanolynx Biologics in Basel, Switzerland in 2025.